shermandarlene+FollowNew Hope for Tough-to-Treat Stomach CancerAmgen’s latest cancer drug just hit a major milestone! Their experimental therapy, bemarituzumab, helped advanced gastric cancer patients live longer when paired with chemo in a big late-stage trial. The catch? Some folks had eye issues and nausea, so doctors are keeping a close watch on side effects. Still, this could be a game-changer for people with few options. More details are coming soon—fingers crossed for more good news! #CancerResearch #MedicalBreakthrough #Amgen #Health #BodyHealth120Share
Michelle Welch+FollowAmgen’s Cancer Drug Shows Real PromiseBig news in cancer research: Amgen’s new drug, Bemarituzumab, just proved it can help late-stage gastric cancer patients live longer when combined with chemo. The trial hit its main goal, and the results are especially hopeful for people whose tumors overexpress the FGFR2b protein. There are some side effects (think eye issues and nausea), but this could be a real game-changer for nearly 1 million new patients each year. Stocktwits is buzzing, but AMGN stock is still a bit of a rollercoaster! #CancerResearch #Amgen #MedicalBreakthrough #Health #BodyHealth332Share
shermandarlene+FollowAmgen’s Cancer Drug Shows Big PromiseAmgen just dropped some major news: their new drug Imdelltra cut the risk of death by 40% for small cell lung cancer patients who didn’t respond to chemo. Plus, people lived over 5 months longer on average compared to standard treatment. Even symptoms like cough and shortness of breath improved! But here’s the twist—despite the breakthrough, retail investors aren’t exactly hyped yet. Would you bet on Amgen after this? #Amgen #CancerResearch #BiotechNews #Health2776Share
